Randomized, Single-dose, Three-way Crossover Study to Assess the Bioavailability of Using SYN006 HFA MDI (Budesonide/Procaterol 180/10mcg) vs Pulmicort pMDI (Budesonide 200 mug) and Meptin Air (Procaterol 10mcg) in Healthy Volunteer.

Trial Profile

Randomized, Single-dose, Three-way Crossover Study to Assess the Bioavailability of Using SYN006 HFA MDI (Budesonide/Procaterol 180/10mcg) vs Pulmicort pMDI (Budesonide 200 mug) and Meptin Air (Procaterol 10mcg) in Healthy Volunteer.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Budesonide/procaterol (Primary) ; Budesonide; Procaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Intech Biopharm
  • Most Recent Events

    • 24 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top